ReviewTherapeutic innovation & regulatory science2023
AI/ML in Precision Medicine: A Look Beyond the Hype.
Review in Therapeutic innovation & regulatory science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- The expanding role of artificial intelligence in personalised medicine: from innovation to individualized care.Frontiers in medicine · 2026Review
- Trends in the applications of artificial intelligence in fatty liver diseases.Hepatology international · 2025Review
- Exploring Artificial Intelligence Readiness in Medical Students: Analysis of a Global Survey.Medical science educator · 2025Article
- A bibliometric analysis of the advance of artificial intelligence in medicine.Frontiers in medicine · 2025Article
- Common Critiques and Recommendations for Studies in Neurology Using Machine Learning Methods.Neurology · 2024Article
- From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa.Oncology and therapy · 2024Article
- The present and future of seizure detection, prediction, and forecasting with machine learning, including the future impact on clinical trials.Frontiers in neurology · 2024Review
- Machine Learning and Artificial Intelligence Applications to Epilepsy: a Review for the Practicing Epileptologist.Current neurology and neuroscience reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial Intelligence (AI) and Machine Learning (ML) are making headlines in medical research, especially in drug discovery, digital imaging, disease diagnostics, genetic testing, and optimal care pathway (personalized care). However, the potential uses and benefits of AI/ML applications need to be distinguished from hype. In the 2022 American Statistical Association Biopharmaceutical Section Regulatory-Industry Statistical Workshop, we convened a panel of experts from FDA and industry to talk about the challenges of successfully applying AI/ML in precision medicine and how to overcome those challenges. This paper provides a summary and expansion on the topics discussed in the panel: the application of AI/ML, bias, and data quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.